Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × OTHER × polatuzumab vedotin × Clear all

Phase

Status

Recruiting 17 Active not recruiting 8 Not yet recruiting 7 Unknown 2 Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Radiotherapy 84 pembrolizumab 77 Cyclophosphamide 67 Cisplatin 58 Magnetic Resonance Spectroscopy 55 Gemcitabine 54 Carboplatin 50 Radiosurgery 48 Paclitaxel 46 Nivolumab 43 Biopsy 37 Fluorouracil 36 Dexamethasone 36 durvalumab 34 Docetaxel 34 Bevacizumab 32 Oxaliplatin 31 Capecitabine 31 fludarabine 30 Surveys and Questionnaires 29 Radiation 29 Leucovorin 29 fludarabine phosphate 27 Melphalan 27 Rituximab 26 Pemetrexed 26 Doxorubicin 26 Irinotecan 24 Cytarabine 24 Etoposide 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04535102 2022-05-09

POLA+BR for Relapsed or Refractory DLBCL

University of Colorado, Denver

Phase 2 Withdrawn

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡